The vector of Bpep based chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human Integrin αvβ6. The T cells are genetically modified through transduction with a lentiviral vector expressing Bpep peptide linked to CD3ζ signaling domains. And the vector product was designed for the treatment of human ovarian cancer.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE